NasdaqGS:MRNABiotechs
Moderna (MRNA) Valuation Check As FDA Reconsiders Flu Shot And EU Backs Combined Vaccine
Moderna (MRNA) is back in the regulatory spotlight after the FDA reversed an earlier refusal and agreed to review its mRNA seasonal flu vaccine, while European regulators backed its combined flu and COVID-19 shot.
See our latest analysis for Moderna.
That regulatory reset has come alongside strong share price momentum, with a 13.77% 1 month share price return, a 99.04% 3 month share price return and a 67.56% year to date share price return at a last close of US$51.71. However, the 3 year...